Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO II: Paricalcitol Injection in Stage 5 CKD With Hemodialysis
2007-005092-33Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and left ventricular hypertrophy (LVH) comparing Paricalcitol injection with Placebo injection (2 arms). Primary endpoint: Change from baseline in left ventricular mass index at 48 weeks. Started Feb 2008; status: completed.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2007-005092-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005092-33.